![Quiver Logo](/static/img/logo-icon.png)
![SLNO logo](https://quiver-logos.s3.us-east-2.amazonaws.com/slno.png)
Soleno Therapeutics, Inc. Common Stock
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SLNO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of SLNO by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by SLNO's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to SLNO
Recent picks made for SLNO stock on CNBC
ETFs with the largest estimated holdings in SLNO
Flights by private jets registered to SLNO
![Quiver Logo](/static/img/logo-icon.png)